Nippon Shinyaku Co., Ltd.
Stock Price Chart
2026/08/19 UpdatedPrice Trend
2026/08/19 UpdatedPrice & Trading Details
2026/08/19 UpdatedPRICE
TRADING
Analyst Recommendations 7 analysts
Updated 2026/08/01Earnings Calendar
Updated 2026/08/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/02/08 | ¥70.00 | ¥149.62 | +113.7% |
| 2025/11/13 | ¥93.09 | ¥111.36 | +19.6% |
| 2025/08/06 | ¥84.91 | ¥122.52 | +44.3% |
| 2025/05/07 | ¥33.74 | ¥59.47 | +76.3% |
Shareholder Composition
Updated 2026/08/01Major Holders
Updated 2026/08/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
845.7K | +5.24% | |
|
Goldman Sachs TRT-Goldman Sachs Intl Small Cap Insights Fd.
|
835.3K | +1.72% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
566.5K | +7.07% | |
|
Victory Portfolios-Victory Trivalent International Small-Cap Fund
|
386.2K | -0.05% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
385.8K | 0.00% | |
|
American Century ETF Trust-Avantis International Small Cap Value ETF
|
339.2K | -30.66% |
Dividend History
Updated 2026/08/16| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥62 | -50.0% |
| 2025 | ¥124 | 0.0% |
| 2024 | ¥124 | +4.2% |
| 2023 | ¥119 | +2.6% |
| 2022 | ¥116 | - |
Financial Performance
2026/08/16 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥137,484M | ¥144,175M | ¥148,255M | ¥160,232M |
| Gross Profit | ¥87,293M | ¥88,195M | ¥98,021M | ¥109,115M |
| Operating Income | ¥32,948M | ¥30,050M | ¥33,297M | ¥35,451M |
| Pretax Income | ¥33,420M | ¥30,625M | ¥33,945M | ¥36,280M |
| Net Income | ¥24,986M | ¥22,812M | ¥25,851M | ¥32,558M |
| EPS | ¥370.97 | ¥338.70 | ¥383.82 | ¥483.40 |
| Operating Margin | 23.96% | 20.84% | 22.46% | 22.12% |
| Balance Sheet | ||||
| Total Assets | ¥219,943M | ¥237,451M | ¥263,404M | ¥283,637M |
| Total Equity | ¥180,584M | ¥195,624M | ¥220,224M | ¥247,027M |
| Total Liabilities | ¥39,359M | ¥41,827M | ¥43,180M | ¥36,610M |
| Cash | ¥60,566M | ¥60,047M | ¥58,094M | ¥55,241M |
| Interest-bearing Debt | ¥2,713M | ¥2,664M | ¥2,872M | ¥2,722M |
| Equity Ratio | 82.10% | 82.38% | 83.61% | 87.09% |
| D/E Ratio | 0.02 | 0.01 | 0.01 | 0.01 |
| Cash Flow | ||||
| Operating CF | ¥21,316M | ¥26,170M | ¥16,289M | ¥36,126M |
| Investing CF | -¥10,037M | -¥17,631M | -¥9,921M | -¥28,877M |
| Financing CF | -¥8,407M | -¥9,605M | -¥9,719M | -¥9,902M |
| Free CF | ¥12,373M | ¥14,442M | ¥6,640M | ¥1,333M |
| Efficiency | ||||
| ROE | 13.84% | 11.66% | 11.74% | 13.18% |
| ROA | 11.36% | 9.61% | 9.81% | 11.48% |
Latest IR Information
-
Notice Regarding the Disposition of Treasury Stock as Restricted Stock
Payment for the disposition of treasury stock as restricted stock completed. Target: 7 internal directors, total 22,379 shares, price 4,048 yen per share, total 90,590,192 yen, disposition date 2026-08-19.
Read more -
Nihon Shinyaku Co., Ltd. Q1 Financial Summary (IFRS) (Consolidated) for Fiscal Year Ending 2027
Consolidated revenue for Q1 was 49,066 million yen, up 24.1% YoY. Operating profit was 12,311 million yen, up 23.4% YoY. Net income attributable to owners of the parent was 10,109 million yen, up 22.5% YoY. Full-year guidance unchanged. Segment-wise, Pharmaceuticals...
Read more -
【Japan Pharmaceutical Industry】Share Buyback and Reward System Introduction ｜ August 2026
Japan Pharmaceutical Industry will dispose of 22,379 shares of common stock at 4,048 yen per share on August 19, 2026, and will introduce a restricted stock compensation system for directors. The purpose of the disposal is to enhance corporate value...
Read more -
【Nihon Shinyaku】2026 Fiscal Year Financial Results｜Sales of ¥170.7 billion (YoY +6.6%)
Consolidated net sales for the fiscal year ending March 2026 were ¥170.71 billion, an increase of 6.6% YoY. Operating profit was ¥35.49 billion, and net income attributable to owners of the parent was ¥29.72 billion. The company maintained steady performance...
Read more -
FY2026 Q3 Financial Summary〔IFRS〕(Consolidated)
For the third quarter of FY2026, revenue was JPY 127.135 billion (4.8% YoY increase) and operating income was JPY 32.333 billion (1.3% YoY decrease), leading to an upward revision of full-year revenue guidance by 1.2%.
Read more
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥4,319
Rating Score: 3.13 (Based on 7 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Europe, Switzerland, the United States, and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Atthena Therapeutics, Inc. to develop ATSN-101 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and Regenex Bio Inc. to develop RGX-121 and RGX-111 for the treatment of mucopolysaccharidosis type I and II. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
